Menu

Scientists Reverse Their Controversial Findings of CRISPR's Off-Target Effects

Last year, researchers claimed the gene-editing method had accuracy issues, but a new whole-genome sequencing analysis by the same team finds otherwise.

Mar 28, 2018
Diana Kwon

ISTOCK, CIPHOTOS

Update (March 30): Nature Methods has retracted the 2017 paper claiming CRISPR could introduce a multitude of unwanted off-target effects. The retraction notice states that since the paper was published, “it has been brought to the journal's and the authors' attention that without parental controls or more analysis of genetic background, it is not certain that the variants reported are due to CRISPR treatment.” It also notes that four of the coauthors don’t agree with the decision to retract.

Last May, stocks of CRISPR-based biotech firms fell sharply after a Nature Methods paper claimed that CRISPR-Cas9 genome-editing introduced a host of unwanted off-target effects in mice. This week, the authors of that paper published a follow-up analysis, published on bioRxiv, reversing their original findings.

“Our previous publication suggested CRISPR-Cas9 editing at the zygotic stage might unexpectedly introduce a multitude of subtle but unintended mutations, an interpretation that not surprisingly raised numerous questions,” the authors write in their new preprint. “[The new] whole-genome-sequencing-level results support the idea that in specific cases, CRISPR-Cas9 editing can precisely edit the genome at the organismal level and may not introduce numerous, unintended, off-target mutations.”

See “Was a Drop in CRISPR Firms’ Stock Warranted?”

When the Nature Methods paper was published last year, it received heavy criticism from the scientific community—to the point where the journal published an “editorial expression of concern,” writing that, “Multiple groups have questioned the interpretation that single nucleotide changes seen in whole-genome sequences of two CRISPR–Cas9-treated mice are due to the CRISPR treatment.”

One of the major methodological flaws critics pointed to was the fact that the authors had compared the CRISPR-edited mice to published sequence data rather than control animals. “The mice you have in your facility have drifted genetically from those that have been sequenced,” Gaétan Burgio, a geneticist at the Australian National University in Canberra who wasn’t involved in the work, told The Scientist at the time. As a result, he added, the analysis couldn’t “tease out which variants are due to the natural genetic variation and which ones are CRISPR-related.”

Since then, other groups have also published analyses countering the observation that CRISPR could introduce a large number of unwanted mutations. One preprint, published on bioRxiv earlier this year, reported that gene-edited mice did not display more mutations than would be expected from the “background rate of [de novo mutations] occurring due to other processes.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.